On this day in 1747, James Lind, a Scottish physician, began what is now generally recognized as the first clinical trial. Among other things, his study of British sailors would provide evidence via a systematic experiment that scurvy could be treated by eating citrus fruits. While it had been generally recognized since antiquity in some parts of the world that citrus staved off this seaman's scourge, Lind's work contributed to creating a more systematic means of helping to ensure the health of the Royal Navy. In turn, one could argue Lind's experiment helped enable Britannia to rule the waves – and thereby European politics – for quite some time to come.
As a patient recruitment company, it’s elementary (though not always obvious to the casual observer) that, with extremely few exceptions, we deal only with the hard-to-enroll studies. Further, it’s not out of the ordinary for us to tackle the (seemingly) impossible-to-enroll studies. So, rare diseases are not uncommon to us, being that they often fall into the latter category of recruit-ability. Indeed, BBK Worldwide (BBK) has had a great deal of experience with rare disease studies. And, if there’s such a thing as a therapeutic category that inspires us more than any other, it’s this one.
In the first part of this blog, we looked at how various Patients’ Bills of Rights – whether created by a state or by a health institution – have handled the idea of patients and clinical research. In this part, we pick up with questions related to the idea of ensuring patients are told about clinical trials for which they may be eligible.
This is the first of a two-part blog that looks at the extent to which a patient’s rights can and should include access to information about clinical trials for which they may be eligible.
I was in the dentist’s office this morning, waiting my turn, leafing through a copy of Smithsonian magazine, the July-August 2013 issue. I came across a short piece on page 20 that got me thinking about a number of things – including clinical trial patient retention.
In part one of this two-part series, I discussed positive trends in patient recruitment and how the sheer range of recruitment- and retention-related services, products, and solutions has exponentially increased, with innovation never stronger. While today’s trends in global patient recruitment are creating the opportunity for greater momentum than ever before, it’s important to strategically consider tactics based on site capabilities and the unique study at hand. How do you do this?
Today’s trends in global patient recruitment are creating the opportunity for greater momentum than ever before. However, it’s important to strategically use only the campaign tactics that bring the greatest value based on site capabilities and the unique study at hand. In part one of Rob’s two-part blog series, he considers today’s positive trends. Look for part two of this series next week where Rob will discuss how best to maximize these trends.
Delays in your IRB or EC submission and review process can not only cause severe headaches for your clinical team members, they can wreak havoc on your patient recruitment campaign’s critical path. Or perhaps better said, an efficient IRB / EC submission management process can mean the difference between maximizing the return on your recruitment investment and your campaign being too little, too late to significantly affect your enrollment completion date.
Here are five basic tips that will help ensure your regulatory body submissions of patient recruitment materials are easy, exacting, and expedited:
It’s time to meet the BBK Worldwide newbies! Aside from all the basic HR processes, and corporate programs BBK newcomers need to learn, the most important part of their initiation to the company is to write a blog. So let’s meet our newest employees at BBK as they embark on an incredible adventure in patient recruitment.
Topics: BBK Worldwide
I’ll cut right to the chase here: posters don’t enroll clinical trials, people do – most specifically, study coordinators, investigators, nurses, and all the staff at your study sites.